I. Sarosi

P. Kostenuik, S. Morony, D. Lacey, 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b

H. Nishina, J. Penninger, I. Kozieradzki, 2000, Nature.

Cytokeratin patterns of liver carcinomas induced by diethylnitrosamine in monkeys.

U. Thorgeirsson, I. Sarosi, J. Bocsi, 1995, Laboratory investigation; a journal of technical methods and pathology.

DREAM Is a Critical Transcriptional Repressor for Pain Modulation

I. Whishaw, M. Ikura, D. Kooy, 2002, Cell.

Anti-Epo receptor antibodies do not predict Epo receptor expression.

C. Begley, I. Sarosi, M. Bass, 2006, Blood.

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.

Daniel J. Freeman, J. Berlin, J. Hecht, 2008, Clinical colorectal cancer.

Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1)

S. Lowe, T. Mak, I. Sarosi, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Synergistic growth factors enhance rat liver proliferation and enable retroviral gene transfer via a peripheral vein.

I. Sarosi, C. Coutelle, M. Themis, 2000, Gastroenterology.

A comparability study of 5 commercial KRAS tests

Daniel J. Freeman, I. Sarosi, S. Patterson, 2010, Diagnostic pathology.

Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.

P. Kostenuik, S. Morony, D. Lacey, 2006, Bone.

Brca1 required for T cell lineage development but not TCR loci rearrangement

T. Mak, J. Marth, J. McPherson, 2000, Nature Immunology.

Bone Metastasis: Can osteoclasts be excluded? (Reply)

S. M. Sims, S. Morony, S. Dixon, 2007, Nature.

Intravenous keratinocyte growth factor protects against experimental pulmonary injury.

I. Sarosi, Jane Guo, T. Ulich, 1998, American journal of physiology. Lung cellular and molecular physiology.

Comparability testing of KRAS mutations and association with efficacy from a phase 3 randomized trial of panitumumab (pmab)

Daniel J. Freeman, E. Van Cutsem, I. Sarosi, 2009 .

Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

D. Lacey, I. Sarosi, J. Delaney, 1998, Cell.

TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling.

S. Morony, D. Lacey, D. Goeddel, 1999, Genes & development.

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

S. Morony, D. Lacey, I. Sarosi, 1998, Genes & development.

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

D L Lacey, P. Kostenuik, S. Morony, 2000, Proceedings of the National Academy of Sciences of the United States of America.

CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin

P. Kostenuik, S. Morony, D. Lacey, 2004, Gut.

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice.

D. Lacey, I. Sarosi, J. Delaney, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.

P. Kostenuik, S. Morony, D. Lacey, 2001, Cancer research.

Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis

P. Kostenuik, S. Morony, D. Lacey, 2000, The Journal of experimental medicine.

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.

Daniel J. Freeman, J. Berlin, J. Hecht, 2008, Clinical colorectal cancer.